Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

A Potent Small-Molecule Inhibitor of the DCN1-UBC12 Interaction That Selectively Blocks Cullin 3 Neddylation

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds

Structural Basis for the Function of DCN-1 in Protein Neddylation

Basis for metabolite-dependent Cullin-RING ligase deneddylation by the COP9 signalosome

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy

Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start?

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

TRAF2 associates with cullin neddylation complex assembly

Anticancer Drug Discovery by Targeting Cullin Neddylation

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Mono-ubiquitination Drives Nuclear Export of the Human DCN1-like Protein Hdcnl1.

A lysine-to-arginine mutation on NEDD8 markedly reduces the activity of cullin RING E3 ligase through the impairment of neddylation cascades.